EmmanuelStylianosAntonarakisMD

Oncology • Minneapolis, MN

Genitourinary Oncology

Professor of Medicine (Oncology), University of Minnesota. Director of Translational Research, Masonic Cancer Center.

Join to view full profile

Dr. Antonarakis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Antonarakis' full profile

Already have an account?

Office
University Of Minnesota
Minneapolis, MN 55455

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
Johns Hopkins UniversityResidency, Internal Medicine, 2004 - 2007
The University of Wales College of MedicineClass of 2003

Certifications & Licensure

MN State Medical License 2021 - 2025
NH State Medical License 2024 - 2024
MD State Medical License 2007 - 2022
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012

Clinical Trials

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer Start of enrollment: 2013 Jan 18
Completed
Phase 1, Phase 2
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Completed
Phase 2
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) Start of enrollment: 2014 Jun 01
Withdrawn
Phase 1, Phase 2
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 2
A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 1
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy Start of enrollment: 2014 Apr 01
Completed
Early Phase 1
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
Active, not recruiting
Phase 2
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC Start of enrollment: 2016 Feb 22
Completed
Phase 2
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer Start of enrollment: 2017 Feb 14
Active, not recruiting
Phase 2
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Start of enrollment: 2017 Mar 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.
Elizabeth U Tran, Eric Royz, Kyra Yamamoto, Samantha Marley, Alexander Song
The Prostate. 2025-01-01
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.
Todd P Knutson, Bin Luo, Anna Kobilka, Jacqueline Lyman, Siyuan Guo
Nature Communications. 2024-12-11
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry
Cancer Cell. 2024-12-09

Journal Articles

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Emmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology

Lectures

Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analy...
2019 ASCO Annual Meeting - 6/1/2019

Other

Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide
Emmanuel Antonarakis, MD, European Urology
https://www.doximity.com/articles/aa1e6f6d-be80-4fdc-91e9-2ccae3c99bc3
UpToDate, Wolters Kluwer Health - 2013-04-10

Authored Content

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-Resistant Prostate Cancer in the Era of Precision OncologyApril 2018

Press Mentions

Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men with Biochemically Recurrent Prostate CancerAugust 21st, 2024
Study Shows How Novel Immunotherapy Helps Fight High-Risk Prostate Cancer, ET HealthWorldApril 8th, 2023
Genomic Profiling: Germline and Somatic Testing - What You Must Know Today - Emmanuel AntonarakisDecember 16th, 2021
Join now to see all